Express Pharma

DECEMBER 25, 2023

Intas Pharmaceuticals has signed an exclusive licensing agreement with mAbxience ( a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma) for biosimilar for Etanercept. Etanercept is a dimeric fusion protein with tumor necrosis factor (TNF) blocking action, that was approved for use over 20 years ago, offering patients a valuable therapeutic option for treating various autoimmune diseases.

Biosimilars 102

Biosimilars 102

Drug Patent Watch

DECEMBER 25, 2023

COREG CR (carvedilol phosphate) Woodward Patent: 7,268,156 Expiration: Dec 27, 2023 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com… The post Drug Patent Expirations for the Week of December 24, 2023 appeared first on DrugPatentWatch - Make Better Decisions.

59

59

Pharmaceutical Technology

DECEMBER 25, 2023

Opaganib is under clinical development by RedHill Biopharma and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma).

52

52

Welltopia Pharmacy

DECEMBER 25, 2023

Fish Oil vs.

98

98

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharmaceutical Technology

DECEMBER 25, 2023

Ribociclib succinate is under clinical development by Novartis and currently in Phase II for Oligodendroglioma.

52

52

Pharmaceutical Commerce

DECEMBER 25, 2023

This year’s PC Podcast episodes ranged in topic, from DSCSA compliance to pharmacovigilance.

52

52

PharmExec

DECEMBER 25, 2023

These stories graced the cover of Pharmaceutical Executive this year

52

52

Pharmaceutical Technology

DECEMBER 25, 2023

Disitamab vedotin is under clinical development by RemeGen and currently in Phase I for Cervical Cancer.

52

52

Pharmacy Times

DECEMBER 25, 2023

From newsworthy moments to groundbreaking research, these were the most-read Alzheimer disease-related articles on Pharmacy Times in 2023.

32

32

Pharmaceutical Technology

DECEMBER 25, 2023

HCW-9218 is under clinical development by HCW Biologics and currently in Phase I for Ovarian Cancer.

52

52

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

Pharmacy Times

DECEMBER 25, 2023

From newsworthy moments to groundbreaking research, these were the most-read pharmacy technician-related articles on Pharmacy Times in 2023.

Pharmacy Technician 29

Pharmacy Technician 29

Pharmaceutical Technology

DECEMBER 25, 2023

Cabometyx is under clinical development by Exelixis and currently in Phase II for Gastric Cancer.

52

52

Pharmacy Times

DECEMBER 25, 2023

From newsworthy moments to groundbreaking research, these were the most-read biosimilar-related articles on Pharmacy Times in 2023.

Biosimilars 26

Biosimilars 26

Pharmaceutical Technology

DECEMBER 25, 2023

ZB-131 is under clinical development by ZielBio and currently in Phase II for Gallbladder Cancer.

52

52

Drug Patent Watch

DECEMBER 25, 2023

This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Finland. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating… The post Which pharmaceutical companies have the most SPCs in Finland? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 59

Pharmaceutical Companies Pharmaceutical Companies 59

Pharmaceutical Technology

DECEMBER 25, 2023

ION-537 is under clinical development by Ionis Pharmaceuticals and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC).

40

40

Pharmaceutical Technology

DECEMBER 25, 2023

Cusatuzumab is under clinical development by OncoVerity and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia).

40

40

Pharmaceutical Technology

DECEMBER 25, 2023

Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia).

40

40

Pharmaceutical Technology

DECEMBER 25, 2023

Magrolimab is under clinical development by Gilead Sciences and currently in Phase II for Metastatic Transitional (Urothelial) Tract Cancer.

40

40

Pharmaceutical Technology

DECEMBER 25, 2023

Sym-023 is under clinical development by Les Laboratoires Servier and currently in Phase I for Esophageal Squamous Cell Carcinoma (ESCC).

40

40

Pharmaceutical Technology

DECEMBER 25, 2023

BDTX-4933 is under clinical development by Black Diamond Therapeutics and currently in Phase I for Central Nervous System (CNS) Tumor.

40

40

Pharmaceutical Technology

DECEMBER 25, 2023

Y-101D is under clinical development by Wuhan YZY Biopharma and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC).

40

40

Pharmaceutical Technology

DECEMBER 25, 2023

Dabrafenib mesylate is under clinical development by Novartis and currently in Phase II for Gastrointestinal Stromal Tumor (GIST).

40

40

Pharmaceutical Technology

DECEMBER 25, 2023

BDTX-4933 is under clinical development by Black Diamond Therapeutics and currently in Phase I for Metastatic Colorectal Cancer.

40

40

Pharmaceutical Technology

DECEMBER 25, 2023

Zanidatamab is under clinical development by Jazz Pharmaceuticals and currently in Phase II for Metastatic Biliary Tract Cancer.

40

40

Pharmaceutical Technology

DECEMBER 25, 2023

Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Atopic Keratoconjunctivitis.

40

40

Pharmaceutical Technology

DECEMBER 25, 2023

BDTX-4933 is under clinical development by Black Diamond Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer.

40

40

Pharmaceutical Technology

DECEMBER 25, 2023

Capivasertib is under clinical development by AstraZeneca and currently in Phase III for Triple-Negative Breast Cancer (TNBC).

40

40

Pharmaceutical Technology

DECEMBER 25, 2023

Taladegib is under clinical development by Endeavor BioMedicines and currently in Phase II for Idiopathic Pulmonary Fibrosis.

40

40

Pharmaceutical Technology

DECEMBER 25, 2023

ADCT-901 is under clinical development by ADC Therapeutics and currently in Phase I for Triple-Negative Breast Cancer (TNBC).

40

40

Pharmaceutical Technology

DECEMBER 25, 2023

NKTR-255 is under clinical development by Nektar Therapeutics and currently in Phase III for Diffuse Large B-Cell Lymphoma.

40

40

Pharmaceutical Technology

DECEMBER 25, 2023

ABSK-021 is under clinical development by Abbisko Therapeutics and currently in Phase I for Tenosynovial Giant Cell Tumor.

40

40

Pharmaceutical Technology

DECEMBER 25, 2023

XB-002 is under clinical development by Exelixis and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC).

40

40

Pharmaceutical Technology

DECEMBER 25, 2023

Y-101D is under clinical development by Wuhan YZY Biopharma and currently in Phase II for Metastatic Colorectal Cancer.

40

40

Pharmaceutical Technology

DECEMBER 25, 2023

Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Myelodysplastic Syndrome.

40

40